(("clinical guidelines"[Resource Type]) OR "practice guideline"[Public - Books

Select item 28215241.

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Top results in this book Table of Contents

Select item 55982962.

Polatuzumab Vedotin (Polivy): CADTH Reimbursement Recommendation: Indication: Large B-cell lymphoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.

Top results in this book Table of Contents

Select item 56504443.

$Epcoritamab (Epkinly): CADTH Reimbursement Recommendation: Indication: Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma Grade 3B after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy [Internet].$

Epcoritamab (Epkinly): CADTH Reimbursement Recommendation: Indication: Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma Grade 3B after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.

Top results in this book Table of Contents

Select item 56209744.

$Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma [Internet].$

Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Top results in this book Table of Contents

Select item 48850005.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1f.)

Top results in this book Table of Contents

Select item 56007066.

$Glofitamab (Columvi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, trFL, or PMBCL, who have received 2 or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy [Internet].$

Glofitamab (Columvi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, trFL, or PMBCL, who have received 2 or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.

Top results in this book Table of Contents

Select item 55908727.

$Axicabtagene Ciloleucel (Yescarta): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy [Internet].$